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Cardiovascular deaths account for about 40% of all deaths of patients with chronic kidney disease (CKD), particularly
those on dialysis, while sudden cardiac death (SCD) might be responsible for as many as 60% of SCD in patients
undergoing dialysis. Studies have demonstrated a number of factors occurring in hemodialysis (HD) that could lead
to cardiac arrhythmias. Patients with CKD undergoing HD are at high risk of ventricular arrhythmia and SCD since
changes associated with renal failure and hemodialysis-related disorders overlap. Antiarrhythmic therapy is much
more difficult in patients with CKD, but the general principles are similar to those in patients with normal renal
function - at first, the cause of arrhythmias should be found and eliminated. Also the choice of therapy is narrowed
due to the altered pharmacokinetics of many drugs resulting from renal failure, neurotoxicity of certain drugs and
their complex interactions. Cardiac pacing in elderly patients is a common method of treatment. Assessment of
patients’ prognosis is important when deciding whether to implant complex devices. There are reports concerning
greater risk of surgical complications, which depends also on the extent of the surgical site. The decision
concerning implantation of a pacing system in patients with CKD should be made on the basis of individual
assessment of the patient.
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Cardiovascular diseases (CVD) are the cause of about
50% of deaths in Europe [1,2]. Mortality of patients with
chronic kidney disease (CKD) is associated with ische-
mic heart disease, myocardial infarction (MI) and sud-
den cardiac death (SCD) [3,4]. CKD is an independent
risk factor for coronary artery disease [5]. Nowadays, a
growing number of people require renal replacement
therapy. In 2003, in Poland, 296 people per million were
on renal replacement therapy and 135 people/million
had functioning renal grafts [6]. Today the main causes
of CKD are the following: diabetic nephropathy, chronic
glomerulonephritis and hypertensive nephropathy [4,5].
In CKD patients common factors associated with
accelerated atherosclerosis such as hyperlipidemia,
hypertension, diabetes, acid–base balance and calcium
phosphate metabolism, anemia, high prevalence of vaso-
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distribution, and reproduction in any mediumhyperhomocysteinemia and inflammatory factors are fre-
quently present [7-9]. Cigarette smoking, male gender,
family history and lack of physical activity are also risk
factors for CVD in CKD [10,11]. The greater the renal
dysfunction, the greater the cardiovascular (CV) risk
[11]. Even mild CKD was associated with higher mortal-
ity, more frequent hospitalization and the necessity of
revascularization after primary coronary artery bypass
graft (CABG) surgery during 7-year follow-up [12]. The
study by Elsayedi et al. [13] revealed that individuals
with CVD and abnormal renal function at baseline are
at the greatest risk of rapid progression towards renal
failure. Friedman et al. [14] suggested that common risk
factors in chronic coronary artery disease (CAD) and
CKD as well as atherosclerosis in the renal microcircula-
tion have the greatest impact on the aforementioned
phenomena. These studies underline the need for the
detection and treatment of CKD in its early stages.
Cardiac arrhythmias are commonly associated with
both heart disease and non-cardiovascular diseases, e.g.
CKD [15]. In most patients cardiac arrhythmias are not
life-threatening, but in the form of malignant ventricularCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Franczyk-Skóra et al. BMC Nephrology 2012, 13:162 Page 2 of 9
http://www.biomedcentral.com/1471-2369/13/162arrhythmia it can lead to sudden cardiac death (SCD)
[15]. In recent years, the opinions concerning risk as-
sessment and the treatment of patients with dangerous
ventricular arrhythmias have changed. The most signifi-
cant change refers to the withdrawal of antiarrhythmic
drug therapy, which itself may increase the risk of
SCD [15]. Currently, the greatest attention is paid to
the removal of the cause of arrhythmia and the use of
non-pharmacological treatments, such as electrical ab-
lation and the implantation of an automatic cardiover-
ter defibrillator (implantable cardioverter defibrillator,
ICD) [15,16].
The current review aims to present the current know-
ledge on pathogenesis and prevention of SCD in patients
with CKD.
Search strategy
We performed a search of the electronic databases
[MEDLINE (1966 – June 2012), EMBASE and SCOPUS
(1965 – June 2012), DARE (1966 – 2012)]. Additionally,
abstracts from national and international cardiovascular
meetings were studied. Where necessary, the relevant
authors of these studies were contacted to obtain further
data. The main data search terms were: arrhythmias,
chronic kidney disease, dialysis, hemodialysis, preven-
tion, renal failure, renal replacement therapy, sudden
cardiac death, sudden death, therapy, treatment.
Review
Cardiac arrhythmias and SCD in patients with CKD
Cardiovascular deaths account for about 40% of all
deaths of patients with chronic renal failure, particularly
those on dialysis [17]. Hypertension which leads to the
occurrence of left ventricular hypertrophy (LVH), heart
failure (HF) and CAD or coexists with them plays the
main role in the development of serious ventricular
arrhythmias [18,19]. LVH essentially increases the risk of
sudden cardiac death [20]. Half of patients with signifi-
cant LVH develop symptoms of HF [13,14]. In the group
of patients with end-stage renal disease (ESRD) and
with hypertrophy (left ventricular mass index [LVMI]
> 125 g/m2) 5-year survival was 20%, and 50% when
the LVMI was <125 g/m2 [13,14]. This is mainly due to
QT prolongation and the increase in its dispersion. QT
prolongation is typical for dialysis patients [13,14].
According to Herzog’s study [21] SCD might be re-
sponsible for as many as 60% of deaths in patients
undergoing dialysis. Another study of 4,120 deaths dur-
ing the 2-year follow-up of 12,833 hemodialysis
patients revealed that the greatest percentage of all
deaths (27%) was caused by sudden cardiac arrest,
while other CV conditions accounted for 20% of all
deaths [15,22]. In the another study by Herzog et al.
[23], deaths from sudden cardiac arrest or arrhythmiaaccounted for approximately 25% of all-cause deaths.
The study by Pun et al. [24] demonstrated an increased
rate of SCD with increasing severity of CKD. Each
10 ml/min/1.73 m2 decline in eGFR was associated
with increased risk of SCD (hazard ratio [HR] = 1.11;
95% CI 1.06–1.17, p < 0.001) [24].
According to studies the frequency of SCD increases
with the time of dialysis treatment and with the time
that passed from their previous dialysis session and it is
highest among individuals with diabetes [25-27]. It was
observed that the frequency of deaths of HD patients
was higher than the expected ratio in the 12 h period
from the beginning of dialysis treatment and on the last
day of the dialysis-free weekend interval. The rate of car-
diac arrest among patients with diabetes who were
undergoing dialysis was 110 events per 1,000 patient-
years at year one and rose to 208 events per 1,000
patient-years at year four [23,25]. In the already men-
tioned study by Herzog et al. [12] the survival rates after
cardiac arrest were 32% at 30 days and 17% at 1 year
after dialysis and dropped to 13% at 1 year in patients
with diabetes.
Among other risk factors for SCD it is worth mention-
ing the hospitalization within 30 days after dialysis and a
decrease of 30 mm Hg in systolic blood pressure (SBP)
during hemodialysis [27]. Moreover, patients with ESRD
and diabetes are at higher risk of sudden death than
non-diabetic ESRD patients [28].
Previous studies have noted a number of factors oc-
curring with HD that could lead to cardiac arrhythmias
[15]. Patients with CKD undergoing hemodialysis are at
high risk of ventricular arrhythmia and SCD since
changes associated with renal failure and hemodialysis-
related disorders overlap. It was revealed that ventricular
arrhythmia is present in 90% and supraventricular
arrhythmia in 80% of dialysis patients [15]. Cardiac
arrhythmias are exacerbated by dialysis and several
hours after it [15]. During dialysis, many changes occur
that favor electrical instability, including disturbances in
serum electrolytes, variations in various metabolite con-
centrations, acid–base balance alterations, the decrease
in circulating blood volume, sympathetic overactivity as
well as inflammation and possibly iron deposition
[15,21,26]. Too low concentration of potassium in the
dialysate, diabetes mellitus, advanced age and dialysis
performed after the weekend break are important factors
that increase the risk of SCD [26,29]. The study by Kar-
nik et al. [26] showed that patients who died in the first
12 h interval had a lower mean serum potassium level in
the prior monthly tests than those dying in the 60–72 h
interval. Moreover, iron overload in ESRD increases the
risk of SCD due to QT prolongation [29].
Concentric hypertrophy leads to the reduced suscepti-
bility of the left ventricle [14,19]. In this situation, the
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could be filled sufficiently to ensure adequate cardiac
output. The rise in filling pressure results in the appear-
ance of symptoms of pulmonary congestion. On the
other hand, the greater sensitivity of the hypertrophic
ventricle results in its higher susceptibility to the occur-
rence of dialysis hypotension [30]. All these conditions
favor the occurrence of serious ventricular arrhythmias
and SCD. LVH increasing the risk of sudden death is
associated with prolongation of the corrected QT inter-
val or with increasing arrhythmogenesis [29].
According to studies also prolonged QT interval, QTc,
and torsade de pointes occurring in CKD and ESRD can
be a cause of sudden cardiac death [31]. Prolonged QTc
in these patients results from inhomogeneity of myocar-
dial depolarization and repolarization following LVH as
well as intercardiomyocytic fibrosis [31,32]. Moreover, in
patients with greater increases in QTc intervals after
hemodialysis, baseline plasma calcium levels are higher
and lower after hemodialysis, which suggests that QTc
prolongation may be a result of calcium hemostasis ab-
normalities and may induce or predispose to sudden
death [33]. A retrospective cohort study conducted on
patients on dialysis QTc interval dispersion which oc-
curred for longer than 74 ms was an independent
predictor of all-cause mortality, CV mortality and
arrhythmia-related mortality [34].
In patients with CKD inflammation can be also a com-
mon trigger of sudden cardiac death as a result of either
premature atherosclerosis, and cytokine-induced plaque
instability or by a direct effect on the myocardium and
the electrical conduction system [35-37]. In this group
of patients the level of toxins, proinflammatory cyto-
kines, inflammatory mediators and reactive oxygen
species (ROS) increases as renal function deteriorates
[36-39]. Elevated levels of inflammatory mediators, the
accumulation of asymmetric dimethylarginine, high
levels of homocysteine as well as raised levels of calcifi-
cation promoters (e.g. osteopontin), diminished levels
of calcification inhibitors (e.g. fetuin-a) and abnormal
calcium–phosphate metabolism are associated with ath-
erosclerosis, atherothrombotic events and incident CV
mortality in patients with CKD and those undergoing
hemodialysis [40-43].
Myocardial ischemia is the most common cause of
malignant ventricular arrhythmias in patients with CKD.
CAD probably causes arrhythmogenesis in patients on
hemodialysis since severe coronary stenosis is associated
with the induction and lengthy persistence of ventricular
arrhythmias during and after hemodialysis [15,44,45].
Arrhythmia also results from fibrosis and cardiac hyper-
trophy. Additional contractions and other changes in
heart rate are its direct triggers. Ischemia, fluid and elec-
trolyte disorders, autonomic neuropathy, anemia, iondisorders caused by the use of diuretics and valvular cal-
cification are the modifying factors, which sometimes
also become the triggering ones [15,21,26,46,47].
Ischemia is probably the most common factor which
modifies the risk or elicits arrhythmia, but the role of
changes in calcium-phosphate metabolism resulting in
heart valve calcification should also be emphasized.
These changes affect the efficiency of the heart and pro-
mote the occurrence of arrhythmias [48,49].
The identification of patients at risk of SCD
The stratification of SCD risk in patients with CKD/
renal failure has been poorly studied so far. Many stud-
ies have shown that elevated levels of troponin T (TnT),
creatine kinase-MB (CK-MB) fraction or C-reactive pro-
tein (CRP) are associated with increased risk of death
from CV causes. However, it is not known whether these
markers also indicate the risk of sudden cardiac death
[4]. The following risk factors for SCD in patients on
dialysis are the most commonly mentioned: (1) demo-
graphic factors: male gender, black race, (2) data from
family history: positive family history, smoking, low
physical activity, (3) cardiovascular disease: hypertension,
left ventricular hypertrophy (LVH), myocardial infarction
(MI), angina pectoris, and (4) other diseases, such as:
diabetes, hyperlipidemia, anemia, hyperparathyroidism,
metabolic acidosis [4,24,35].
Patients at high risk of SCD can be also identified on
the basis of markers of coronary ischemia such as ische-
mia modified albumin (IMA) or cardiac troponin [50].
Ischemia modified troponin is a novel biomarker which
predicted all-cause mortality in ESRD patients with a
sensitivity and specificity of 76% and 74%, respectively
[50]. Elevated cardiac troponin (≥0.06 μg/l) predicted
mortality with a sensitivity of 75% and a specificity of
72% [50]. Cardiac mortality risk was 7-fold higher in
patients with elevated levels of both IMA and cardiac
troponin (OR 7.12, 95%CI 4.14–10.12, p = 0.005) [50].
According to studies also severely impaired myocardial
fatty acid metabolism due to recurrent myocardial ische-
mia may indicate those patients on dialysis who are at
high risk of SCD [51].
Other small studies have shown that heart rate vari-
ability analysis and the assessment of baroreceptor sensi-
tivity may also have predictive value. Impaired baroreflex
effectiveness and sensitivity and obstructive sleep apnea
may increase the risk of sudden death [52]. In the study
of Johansson et al. [52] baroreflex sensitivity was
reduced by 51% and the baroreflex effectiveness index
by 49% in patients with hypertension and stage 4 or 5
CKD in comparison to age-matched healthy controls.
According to another Johansson et al. [53] study,
reduced baroreflex sensitivity was an independent pre-
dictor of SCD. The results of the German Diabetes
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people who died as a result of sudden cardiac arrest
were found dead in bed in the morning, which according
to the investigators might have been related to obstruct-
ive sleep apnea [54]. However, there were no measures
or objective data available to support this conclusion.
Moreover, this study revealed that low baseline homoar-
ginine concentration was a strong risk factor for SCD
and HF death during 4-year follow-up [55]. Another
analysis of 4D data showed that poor glycemic control
and vitamin D deficiency were also strongly associated
with the incidence of SCD in dialysis patients [56]. Des-
pite the progress of technology and numerous studies,
current knowledge concerning the evaluation of risk
SCD factors is still too limited to sufficiently explain the
excess rate of such deaths in dialysis patients [55].
Antiarrhythmic management in CKD patients
Antiarrhythmic therapy is much more difficult in
patients with CKD, but the general principles are similar
to those in patients with normal renal function. First of
all, the cause of arrhythmias should be found and elimi-
nated. In patients with CKD it is mainly based on very
rigorous control of water and electrolyte balance. Antiar-
rhythmic drugs can be used in this group of patients but
with limited effectiveness. The choice of therapy is lim-
ited due to the altered pharmacokinetics of many drugs
resulting from renal failure, neurotoxicity of certain
drugs and their complex interactions [57]. Beta-blockers
should be the drugs of choice because of their lower risk
of proarrhythmia [58,59]. The Multicenter Automatic
Defibrillator Implantation Trial-II (MADIT II) study
demonstrated that the use of these drugs was associated
with a significant reduction in SCD risk in patients with
CKD [60]. In another randomized controlled trial, carve-
dilol therapy reduced morbidity, all-cause and cardiovas-
cular mortality (by 29.3%) in dialysis patients with ESRD
and dilated cardiomyopathy [61]. The large (43,200
hemodialysis patients) retrospective study by Pun et al.
revealed that beta-blockers were more frequently pre-
scribed to patients who survived than to those who died
from SCD (53% vs 40%, or 0.59, 95% CI 0.43–0.80,
p = 0.0007) [62]. Moreover, according to this study beta-
blockers were associated with a significantly lower risk
of death at 24 h and 6 months after cardiac arrest [62].
Amiodarone seems to be the most effective antiar-
rhythmic drug used in the treatment of ventricular
arrhythmia and atrial fibrillation. However, its numerous
non-cardiac actions should be kept in mind [63]. In dia-
lysis patients the reduction of SCD risk was achieved
through the introduction of bicarbonate dialysis, modifi-
cation of dialysis fluid composition (potassium and cal-
cium concentration) depending on the clinical situation,
rapid restoration of water-electrolyte and acid–basebalance as well as monitoring of heart rhythm [64].
However, it is common knowledge that the implantation
of automatic cardioverter-defibrillators (ICD) both as a
primary and secondary prevention is the only effective
way of preventing SCD [57]. Though ICD implantation
decreases the risk of SCD, there are hardly any trials
concerning the use of ICD in patients with advanced
renal insufficiency [14]. The ICD is a device that works
symptomatically and thus it does not decrease the risk
of arrhythmic events, in contrast to coronary revascular-
ization, optimal pharmacotherapy or cardiac resynchro-
nization in HF [65,66]. Published data (MADIT II study)
show that ICD implantation contributed to reduction in
total mortality in primary and secondary prevention, and
reduction in mortality from arrhythmia causes in a
population of patients after myocardial infarction [67].
On the basis of the results of the aforementioned stud-
ies, guidelines considering the indications for ICD im-
plantation were defined [68]. According to them, an ICD
should be implanted as the secondary prevention in
patients who survived cardiac arrest in the course of ma-
lignant ventricular arrhythmias unless arrhythmia oc-
curred within the first 24-48 h after fresh myocardial
infarction (class I of recommendation, level A of evi-
dence). During the first 24-48 h ventricular arrhythmia
is a symptom of acute ischemia, and treatment should
refer to immediate and optimal coronary revasculariza-
tion [68]. In the primary prevention of SCD, ICD should
be implanted within 40 days after MI in patients with
the EF 30-40%, in NYHA class II-III, receiving optimal
pharmacological treatment and with predicted survival
in good functional condition for at least one year (class I
of recommendation, level A of evidence) [68].
The analysis of these recommendations reveals the ex-
istence of the so-called ‘grey area’ between 48 h and
40 days after MI. This early post-myocardial period
raises the most controversy concerning SCD risk stratifi-
cation and the possible implantation of ICD in primary
prevention of SCD [69]. It is known that the risk of SCD
is highest in that period. In the Valsartan in Acute Myo-
cardial Infarction Trial (VALIANT) [70], 19% of patients
died suddenly or were resuscitated within 30 days after
myocardial infarction and 70% of all SCD occurred dur-
ing the first year after MI. Although ICD implantation
reduced the number of arrhythmic deaths, patients with
implanted ICD died more often due to non-arrhythmic
causes (non-SCD) [68-70].
On the basis of the aforementioned studies it can be
concluded that while the ICD effectively interrupts ven-
tricular arrhythmias in a population of patients who
would suddenly die from arrhythmic causes without this
device, it also contributes to the increased number of
non-arrhythmic deaths. It was hypothesized that high
energy therapies might have an adverse impact on the
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[68,71]. The MADIT II study demonstrated that ad-
equate ICD cardioversion/defibrillation increases three-
fold and inadequate defibrillation increases twofold the
overall mortality [67]. This indicates high importance of
correct and optimal programming of implanted devices
in order to minimize the frequency of inappropriate ICD
therapy. It is also known that the benefits of the
implanted ICD increase with time after MI. The MADIT
II study revealed a reduction in mortality and the great-
est benefit from ICD implantation after over 18 months
after myocardial infarction [67,69].
The study by Dasgupta et al. [72] conducted on 41
patients with ESRD and 123 controls demonstrated high
complication rates for cardiac rhythm management
devices (permanent pacemakers or implantable cardio-
verter-defibrillators) in this group of patients. Pneumo-
thorax requiring a chest tube, pocket infection requiring
device extraction, or thrombosis occurred in 29% of
ESRD patients versus 5% of controls (p < 0.001) while
minor complications occurred in 17% of ESRD patients
versus 6% of controls (p < 0.03). However, no fatal com-
plications were seen in either group [72]. A retrospective
study of patients with ICD implanted due to primary or
secondary indications revealed that renal insufficiency
was a strong predictor of appropriate ICD shocks [73].
One-year incidence of appropriate ICD shock was 37.5%
for patients on dialysis and 10.7% for those not on dialy-
sis (p < 0.0001) [73].
The study of patients with or without CKD who
received an ICD for primary prevention of sudden car-
diac death demonstrated that 1-year survival of patients
with CKD was lower (61.2%) than that of patients with-
out CKD (96.3%) (p < 0.00001) [74]. In this study CKD
was the most significant independent predictor of mor-
tality (HR 10.5, 95%CI 4.8–23.1, p < 0.00001) [74]. The
study of Korantzopoulos et al. [75], which demonstrated
increased mortality in patients who receive ICD therapy,
suggested that patients with advanced renal insufficiency
could be less responsive to ICD therapy, probably due to
higher defibrillation thresholds. Until the reasons for
that phenomenon are explained it seems rational that
patients with CKD and implanted ICD should be more
frequently tested using the technique of programmed
ventricular stimulation than patients with normal renal
function [75]. This will help to determine the threshold
of effective defibrillation. It is also possible that the inci-
dence of infectious complications related to ICD im-
plantation may be greater in this group. These and other
factors are responsible for the lower frequency of ICD
implantation in dialysis patients who survived cardiac
arrest [75].
However, according to Herzog et al. [76] ICD implant-
ation in cardiac arrest survivors on dialysis is associatedwith greater survival. They observed that estimated 1-,
2-, 3-, 4-, and 5-year survival after day 30 of admission
in the ICD group were higher (71%, 53%, 36%, 25%, and
22%, respectively) in comparison to the no-ICD group
(49%, 33%, 23%, 16%, and 12%) (p < 0.0001). In this study
ICD implantation was associated with a 42% reduction
in death risk [76].
It should be kept in mind that not all arrhythmic
events are interrupted by the ICD, as it is in the case of
e.g. pulseless electrical activity after ICD testing, per-
manent ventricular tachycardia or acute HF after defib-
rillation. Moreover, not every SCD results from
arrhythmic causes or even CV-related ones. SCD
(defined as sudden death occurring within one hour of
the beginning of clinical symptoms) may well be the re-
sult of pulmonary embolism, aortic aneurysm dissection,
stroke, etc. [68,77]. According to publications, worse
survival and higher incidence of SCD were observed in
patients with both ICD and CKD compared to patients
with normal renal function [68,77-80].
According to the study by Cuculic et al. [14,74] in
patients receiving an ICD for primary prevention of
SCD, CKD significantly reduced long-term survival,
which may limit the benefits of ICD therapy in this
population. When making the decision concerning im-
plantation of a ICD for primary prevention of sudden
cardiac death in patients with CKD, the patient’s age and
the stage of kidney disease should be taken into account
[78]. According to this study ICDs reduce mortality in
patients with stage 1 and 2 CKD. The benefits of ICD
implantation are less notable in patients with stage 3–5
CKD [78]. These results could be explained by a higher
procedural risk and complications in addition to
decreased life expectancy in patients with advanced
CKD [14,78]. Moreover, benefits of ICD implantation
are age-dependent. Cardioverter-defibrillator implant-
ation seems to be preferential in patients aged <80 years
with GFR 30–59 ml/min/1.73 m2, aged <75 years with
GFR 15–29 ml/min/1.73 m2 and aged <65 years with
GFR <15 ml/min/1.73 m2 [78].
A prospective study of the effectiveness of automatic
cardioverter-defibrillators in a population of CKD
patients is particularly necessary due to the very high in-
cidence of sudden death in these patients. The role of
drugs/invasive therapies in the prevention and treatment
of SCD in CKD patients are briefly summarized in
Table 1.
The role of electrostimulation
Pathological bradyarrhythmias (<50/min) resulting from
sinus node or AV conduction dysfunction are respon-
sible for 15-20% of SCDs [67,68]. Therefore, the im-
plantation of classic one- and two-electrode stimulators,
as well as pacemaker systems, is extremely important in
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1232 MADIT II study. Reduced risk of arrhythmic mortality












729 Significantly reduced risk of death with beta-
blockers* at 24 h** at the 6-month time points***.
Strongly predictive for survival.
* OR 0.32; 95%
CI 0.17-0.61
[62]
** p = 0.005
*** p < 0.001






114 Reduced morbidity* and mortality** in dialysis
patients with dilated cardiomyopathy. Carvedilol use
is recommended in all dialysis patients with chronic
HF.
* p < 0.00001 [61]
** p < 0.01









Patients with renal insufficiency are more prone to
develop ventricular tachyarrhythmia and receive
appropriate ICD shocks2.
* p < 0.001 [72]
ICD Patients with renal
insufficiency and ICD
Prospective 230 Renal insufficiency is a strong predictor of ICD
shocks and antitachycardia pacing.
p = 0.02 [73]






In patients receiving an ICD for primary prevention






ICD CKD with ICD* or eGFR
< 60 mL/min/1.73 m2**
with ICD
Meta-analysis 3010 CKD is associated with increased mortality in
patients who receive ICD therapy.




HR = 3.06, 95%
CI 2.31-4.04, p
< 0.001**
ICD Dialysis patients with
ventricular fibrillation/








Estimated 1 to 5-year survival after ICD implantation
was better than in the non-ICD group*. ICD
implantation was independently associated with a
42% reduction in death risk**




ICD CKD patients with ICD Prospective
study
- The beneficial effect of an ICD for primary
prevention of SCD in CKD patients depends
primarily on the patient’s age and stage of renal
disease. ICD implantation in stages I-II reduces
mortality, but in more advanced stages, advantages
are less pronounced and are age-dependent due to
higher procedural risk and decreased life
expectancy.
- [78]
ABBREVIATIONS: SCD, sudden cardiac death; CKD, chronic kidney disease; MADIT II, Multicenter Automatic Defibrillator Implantation Trial-II; HR, hazard risk; OR,
odds ratio; HF, heart failure; VALIANT, Valsartan in Acute Myocardial Infarction Trial; ICD, implanted cardioverter-defibrillator; ESRD, end-stage renal disease, RR, risk
reduction.
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sick sinus syndrome (SSS), involves the entire group of
sino-atrial disorders, from sinus bradycardia to sinus in-
hibition or so-called bradycardia-tachycardia syndrome.
Sinus node disease occurs much more frequently in eld-
erly patients and it is believed to be a major reason for
permanent pacemaker implantation in this group
[67,68,81,82]. Sinus node degeneration progresses with
age, which means the reduction of the number of nodal
cells, and the increase in the content of connective tissue
and fat mainly in the nodal area. Symptoms of this dis-
ease include decreased exercise tolerance and cognitive
impairment (mainly in elderly patients) due to bradycar-
dia and chronotropic insufficiency resulting from the in-
ability to properly increase heart rate in response toexercise. Atrial tachyarrhythmia occurring after a sinus
pause may increase the heart rate so strongly that it may
lead to hypotension and loss of consciousness. Elderly
people lose consciousness easily due to numerous other
contributory factors, such as baroreceptor failure, poly-
therapy and changes in the cerebral vessels [67,68,81,82].
The determination of indications for pacemaker im-
plantation in patients with sinus node disease should be
preceded by a detailed differential diagnosis including
cerebral circulation disorders, which can also be a cause
of dizziness, balance impairment or loss of conscious-
ness [82].
The selection of stimulation type in patients with sinus
node disease should depend on the type of disorders and
symptoms. CKD is not a contraindication for the
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minimization of right ventricular stimulation. Such pro-
cedures are validated by the improvement of the quality
of life resulting from the limitations of atrial fibrillation
attacks, which are in elderly patients a common cause of
significant cardiac decompensation. Moreover, in
patients with sinus node disease, there is a risk of future
atrioventricular conduction disorders [68,82].
Implantation of cardiac resynchronization system
Cardiac resynchronization therapy (CRT) with or with-
out ICD is used to treat advanced HF accompanied by
inter- and intraventricular conduction abnormalities
leading to significant desynchronization of chambers
[83,84]. CRT is complementary to optimal drug therapy.
The Comparison of Medical Therapy, Pacing and Defib-
rillation in Heart Failure (COMPANION) study com-
pared the clinical effects of CRT-D or CRT-P system
implantation [84,85]. The analysis of the results from
this study revealed that only CRT-D system implantation
was associated with a significant reduction in the risk of
SCD. According to the 2010 guidelines concerning HF
and cardiac resynchronization therapy, CRT should be
implanted in the following patients: (1) with heart failure
(NYHA class III or IV), EF <35%, QRS > 120 ms, sinus
rhythm, treated with a stable pharmacological medical
regimen. Furthermore, patients in NYHA class IV should
not be hospitalized for HF during the month prior to de-
vice implantation and their expected survival should be
longer than 6 months (I/A); (2) with heart failure in
NYHA class II, EF <35%, QRS > 150 ms, sinus rhythm,
treated with a stable pharmacological medical regimen
(I/A) [86].
The implantation of CRT systems is more and more
common due to both the extension of indications as well
as greater availability of this method. The effectiveness
of resynchronization was not assessed in patients with
CKD. However, it seems highly possible that this method
can be effective also in patients with CKD and symp-
toms of systolic HF and contraction asynchronism.
Conclusions
Over the last decade, numerous studies have confirmed
the strong association between CKD and an increased
risk of cardiovascular diseases. The decision concerning
the implantation of a pacing system in patients with
CKD should be made on the basis of careful individual
assessment of the patient. Treatment of arrhythmias in
patients with CKD is more difficult than in patients
with preserved renal function. The control and correc-
tion of electrolyte disturbances, the treatment of cardio-
vascular disease, and the implantation of ICD in
patients at highest risk are very important in this group
of patients [87-91].Competing interests
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